Swiss National Bank Invests $1.17 Million in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Swiss National Bank purchased a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 4th quarter, Holdings Channel reports. The fund purchased 110,200 shares of the company’s stock, valued at approximately $1,168,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after buying an additional 694,385 shares during the last quarter. State Street Corp raised its holdings in Neumora Therapeutics by 65.3% in the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after acquiring an additional 707,409 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Neumora Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock worth $7,464,000 after acquiring an additional 5,899 shares during the last quarter. Cerity Partners LLC acquired a new stake in Neumora Therapeutics during the third quarter worth approximately $3,209,000. Finally, Wexford Capital LP grew its position in shares of Neumora Therapeutics by 90.1% in the third quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock valued at $2,878,000 after purchasing an additional 103,285 shares during the last quarter. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Trading Down 6.4 %

Shares of NASDAQ:NMRA opened at $1.03 on Friday. The firm has a 50 day moving average of $1.61 and a 200-day moving average of $7.55. Neumora Therapeutics, Inc. has a 12 month low of $1.02 and a 12 month high of $17.19. The stock has a market capitalization of $166.84 million, a PE ratio of -0.55 and a beta of 2.59.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, research analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on NMRA shares. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Bank of America lowered their price target on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. William Blair downgraded shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Finally, Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.14.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.